Filter by Year:
Press Releases
-
May 08, 2023
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
-
Apr 25, 2023
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
-
Apr 24, 2023
Foghorn Therapeutics Provides an Update on FHD-609
-
Apr 10, 2023
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
-
Apr 06, 2023
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
-
Mar 09, 2023
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
-
Mar 01, 2023
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
-
Jan 09, 2023
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023